Advertisement

Valacyclovir HCl (Valtrex™): An Acyclovir Prodrug with Improved Pharmacokinetics and Better Efficacy for Treatment of Zoster

  • M. Lynn Smiley
  • Alison Murray
  • Paulo de Miranda
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

Oral administration of acyclovir (9-[2-hydroxyethoxy)methyl]-9H-guanine, Zovirax®) is effective treatment for mucocutaneous infections caused by herpes simplex virus type I (HSV1) and herpes simplex virus type 2 (HSV-2). In zoster, a debilitating disease caused by reactivation of varicella zoster virus (VZV), acyclovir accelerates healing, and decreases the incidence, severity, and duration of pain.1,2,3,4,5,6,7,8,9,10 However, as the oral bioavailability of acyclovir is limited (15–21%), it is difficult to achieve the high plasma drug concentrations required to inhibit VZV, and herpes viruses which are relatively insusceptible to acyclovir in vitro, e.g. Epstein-Barr virus (EBV), cytomegalovirus (CMV) and Hï-íV-6. This limited bioavailability of acyclovir necessitates frequent dosing (5 times daily) and may not provide maximum therapeutic benefit. Thus, for the treatment of zoster and the suppression of CMV infections, higher oral acyclovir doses than are effective for the treatment of herpes simplex viruses infections or, in some cases, intravenous acyclovir are necessary in order to demonstrate benefit.

Keywords

Herpes Simplex Virus Type Herpes Zoster Genital Herpes Bone Marrow Transplant Recipient Oral Acyclovir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Huff JC, Bean B, Balfour HH Fr, et al. Therapy for herpes zoster with oral acyclovir. Am J Med 1988; 85: 84–89.PubMedCrossRefGoogle Scholar
  2. 2.
    Morton P and Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. New Zealand Medical Journal 1989; 102: 93–95.PubMedGoogle Scholar
  3. 3.
    Wood MJ, Ogan PH, McKendrick MW et al. Efficacy of oral acyclovir treatment of acute herpes zoster. American Journal of Medicine 1988; 85: 79–83.PubMedGoogle Scholar
  4. 4.
    Bean B, Braun C, Balfour HH Jr. Acyclovir therapy for acute herpes zoster. Lancet 1982; 2: 118–121.PubMedCrossRefGoogle Scholar
  5. 5.
    Peterslund NA, Seyer-Hansen K, Ispen J et al. Acyclovir in herpes zoster. Lancet 1981; 2: 827–830.PubMedCrossRefGoogle Scholar
  6. 6.
    Whitley RJ. Therapeutic approaches to varicella-zoster virus infections. Journal of Infectious Diseases 1992; 166: S51 - S57.PubMedCrossRefGoogle Scholar
  7. 7.
    Balfour HH Jr, Bean B, Laskin OR et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. New England Journal of Medicine 1983; 308: 1448–1453.PubMedCrossRefGoogle Scholar
  8. 8.
    Shepp DH, Danliker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients: A randomised comparison of acyclovir and vidarabine. New England Journal of Medicine 1986; 314: 208–212.PubMedCrossRefGoogle Scholar
  9. 9.
    Huff JC, Crucker JL, Clemmer A et al. Effect of oral acyclovir on pain resolution in herpes zoster: A re analysis. Journal of Medical Virology 1993;Suppl 1: 93–96.Google Scholar
  10. 10.
    Crooks RI, Fiddian AP, Jones DA. Zoster-associated chronic pain: An overview of clinical trials with acyclovir. Scandinavian Journal of Infectious Diseases 1991; 78: 62–68.Google Scholar
  11. 11.
    Nusinoff-Lehrman S, Smiley L, Szczech G. Update on acyclovir prodrugs in Antiviral Chemotherapy; New directions for clinical application and research 1993; 3: 97–104.Google Scholar
  12. 12.
    Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, deMiranda P, Smiley ML. Pharmacokinetics of the acyclovir prodrug valacyclovir, after escalating single-and multiple-dose administration to normal volunteers. Clinical Pharmacology and Therapeutics 1993; 54: 595–605.PubMedCrossRefGoogle Scholar
  13. 13.
    Burnette TC and deMiranda P. Metabolic disposition the acyclovir prodrug valacyclovir in the rat. Drug Metab. and Dispos. 1994; 22: 60–64.Google Scholar
  14. 14.
    deMiranda P and Burnette TC. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in Cynomolgus monkeys. Drug Metab. and Dispos. 1994; 22: 55–59.Google Scholar
  15. 15.
    Smith C, Klein A and Zimmerman T. Influx of valaciclovir in Cynomolgus monkey intestinal brush border membranes in transporter-mediated and enhanced over acyclovir. Progr. Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother. 1993 Abstr. 1705.Google Scholar
  16. 16.
    Burnette TC and deMiranda P. Purification and characterization of an enzyme from rat liver that hydrolyses 256U87, the L-valyl ester prodrug of acyclovir (ZOVIRAX®). Antiviral Res. 10, Abstr. 132.Google Scholar
  17. 17.
    deMiranda P, Burnette TC. Smith C. Harrington J, and Reardon J. Mechanisms of the enhanced oral bioavailability of acyclovir with the prodrug valacyclovir HDL (VALTREXTM) Progr. Abstr. 34th Intersci. Conf. Antimicrob. Agents Chemother. 1994 Abstr. A70.Google Scholar
  18. 18.
    Wang L, Schultz M, Weller S, Smiley ML, Blum MR. Pharmacokinetics and safety of valacyclovir HCI, an acyclovir prodrug, in geriatric volunteers with and without concomitant diuretic therapy. Journal of the American Geriatric Society 1993:41(Suppl 10): SA23.Google Scholar
  19. 19.
    First MR, Blum MR, Brennan P. Connors J, Dummer S. Lee I et al. Pharmacokinetics of 256U87, an acyclovir prodrug, in renal transplant patients. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics, 1993.Google Scholar
  20. 20.
    Gluckman E, Milpied N, Prentice GH, On NT, Parke A, Coggon GL. Oral valacyclovir HCI (Valtrex) produces acyclovir exposure comparable to that following intravenous acyclovir in allogenic bone marrow transplant patients. Abstract presented to 20th European Cooperative Group for Bone Marrow Transplantation, Harrowgate, UK, March 1994.Google Scholar
  21. 21.
    Jacobson MA, Gallant J, Wang LH, Coakley D, Weller S, Gary D, Squires L et al. Phase I trail of valacyclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrobial Agents and Chemotherapy 1994; 38 (7): 1534–1540.PubMedCrossRefGoogle Scholar
  22. 22.
    Burgoon CF Jr, Burgoon JS, Baldridge GD. The natural history of herpes zoster. Journal of the American Medical Association 1957: 164: 265–269.PubMedCrossRefGoogle Scholar
  23. 23.
    Rockley P, Tyring S, Smiley M and The international Valaciclovir HSV Study Group. Valaciclovir is equally safe and effective for the treatment of recurrent genital herpes simplex virus infections as is acyclovir but with a more convenient dosing. Clinical Research 1993: 41: 778A.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • M. Lynn Smiley
  • Alison Murray
  • Paulo de Miranda

There are no affiliations available

Personalised recommendations